To evaluate the efficacy of an integrated yoga module as an intervention for reducing epilepsy related stigma in persons with epilepsy in India

Interventions for stigma for persons with epilepsy in India

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/04/008385

Enrollment

160

Registered

2017-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Epilepsy Health Condition 2: G409- Epilepsy, unspecified

Interventions

Intervention1: Integrated Yoga Module for Persons with Epilepsy (IYMPE): In addition to usual medical care, patients will be administered an Integrated yoga module for persons with epilepsy consisting

Eligibility

Inclusion criteria

Inclusion criteria: 1. Consenting 2. Persons diagnosed as having epilepsy [As per definition of ILAE, at least two or more unprovoked or reflex seizures > 24hr apart or one unprovoked or reflex seizure with a probability of recurrence of at least 60% or diagnosis of an epilepsy syndrome]. 3. Persons with epilepsy who screen positive on Kilifi Stigma Scale for epilepsy.

Exclusion criteria

Exclusion criteria: 1) Non-Consenting 2) Persons with epilepsy having any other clinically significant confounding physical/ cognitive disability or stigmatizing condition (as determined by the attending physician). 3) Practicing mediation/ yoga regularly or sporadically for a period of three months or more prior to the recruitment period

Design outcomes

Primary

Measure	Time frame
a) To evaluate the efficacy of an Integrated Yoga Module for Persons as intervention to reduce the stigma in persons with epilepsy as measured by Kilifi Stigma Scale.Timepoint: Baseline, 3 months and follow-up at 6 months	—

Secondary

Measure	Time frame
To assess the changes in behavior, cognition and quality of Life in intervention and comparative arm using the following measures: Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder Assessment-7 (GAD-7), Mindful Attention Awareness Scale (MAAS), Brooding Subscale of Response Styles Questionnaire (RSQ), Emotion Regulation Questionnaire (ERQ),Montreal Cognitive Assessment (MoCA), and Quality of Life in Epilepsy-10 (QoLIE-10)Timepoint: Baseline, 3 months and 6 months follow-up;To assess the changes in seizure frequency (as compared to the comparator group) after the administration of intervention.Timepoint: Baseline, 3 months and 6 months follow-up;To study the shift in EEG power spectra using high density EEG post intervention (as compared to the comparator arm) and their correlation with change in stigma scores.Timepoint: Baseline, 3 months	—

Measure

Time frame

To assess the changes in behavior, cognition and quality of Life in intervention and comparative arm using the following measures: Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder Assessment-7 (GAD-7), Mindful Attention Awareness Scale (MAAS), Brooding Subscale of Response Styles Questionnaire (RSQ), Emotion Regulation Questionnaire (ERQ),Montreal Cognitive Assessment (MoCA), and Quality of Life in Epilepsy-10 (QoLIE-10)Timepoint: Baseline, 3 months and 6 months follow-up;To assess the changes in seizure frequency (as compared to the comparator group) after the administration of intervention.Timepoint: Baseline, 3 months and 6 months follow-up;To study the shift in EEG power spectra using high density EEG post intervention (as compared to the comparator arm) and their correlation with change in stigma scores.Timepoint: Baseline, 3 months

—

Countries

India

Contacts

Public ContactK Kaur

All India Institute of Medical Sciences, New Delhi, India

mtripathiaiims@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 9, 2026